Dosing Begins in Phase 2 Study of Rigosertib for Skin Cancer in RDEB

Dosing Begins in Phase 2 Study of Rigosertib for Skin Cancer in RDEB

292742

Dosing Begins in Phase 2 Study of Rigosertib for Skin Cancer in RDEB

The first patient has been dosed in a Phase 2 trial investigating rigosertib as a treatment for cases of recessive dystrophic epidermolysis bullosa (RDEB) involving an aggressive skin cancer called squamous cell carcinoma (SCC). RDEB patients are at high risk of developing SCC. “We are pleased with the advancement of our … programs with rigosertib, and to provide rigosertib in support of this important Phase 2 investigator-sponsored study,” Steven M. Fruchtman, MD, president and CEO…

You must be logged in to read/download the full post.